NR1H4 and seborrheic dermatitis: Considering that MF is a clinical drug against persistent asthma as well as a well-established treatment for a variety of inflammatory corticosteroid-responsive dermatoses, such as chronic hand eczema, atopic dermatitis (AD), seborrhoeic dermatitis, and psorias28, our findings reveal an alternative template for design of FXR ligands with therapeutic potential to rapid clinical applications by providing a safe lead compound.